Golocdacimab  (Synonyms: MEDI6570)

Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus^[1][2].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

OLR1

Gocdacimab (MEDI6570) has the potential to improve cardiovascular-related pathological conditions in type 2 diabetes by blocking the LOX-1 signaling pathway and regulating related biomarkers and signaling pathways, with the relevant mechanisms of action as follows^[3]:
1. Directly bind to and block the LOX-1 receptor:
MEDI6570 specifically binds to LOX-1, antagonizes its interaction with ligands such as oxLDL, and inhibits the activation of the LOX-1 signaling pathway. Abnormal activation of the LOX-1 signaling pathway is a key contributor to increased cardiovascular risk in type 2 diabetes.
2. Regulate key inflammatory biomarkers:
It regulates inflammatory biomarkers such as IL-16 and IL-18 that are associated with the LOX-1 signaling pathway. These biomarkers represent potential nodes linking the LOX-1 signaling pathway to cardiovascular risk. By altering their expression levels, MEDI6570 interrupts the transmission of cardiovascular risk mediated by the LOX-1 signaling pathway and improves inflammation-related pathological conditions in patients with type 2 diabetes.
3. Affect neutrophil-related pathways:
It induces the production of neutrophil-related biomarkers such as CEACAM8, PRTN3, PGLYRP1, CPB1, GRN and LTBR, indicating that it can regulate neutrophil-related pathways. Neutrophils exert potential effects in LOX-1-mediated pathological responses, and this regulatory effect further interferes with the downstream pathological impacts of the LOX-1 signaling pathway.
4. Inhibit abnormal activation of multiple LOX-1-related pathways:
It regulates multiple pathological pathways associated with the LOX-1 signaling pathway, including oxidative stress, apoptosis, cell adhesion and migration, improves pathological changes caused by abnormalities of these pathways in patients with type 2 diabetes, and reduces the risk of cardiovascular complications.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4973  [NCBI]

4973

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.64 kDa

2418540-63-1

Liquid

Colorless to light yellow

[Golocdacimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• [1]. Varma V, et al. Identification of Response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes[J]. Circulation, 2022, 146(Suppl_1): A11971-A11971.

  [2]. Finocchiaro S, et al. Anti-inflammatory pharmacotherapy in patients with cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2025;11(8):712-728.  [Content Brief]

  [3]. Vavere A L, et al. The safety and efficacy of single and multiple ascending doses of MEDI6570 in participants with type 2 diabetes mellitus[J]. Journal of the American College of Cardiology, 2021, 77(18_Supplement_1): 1189-1189.